|

AMICUS THERAPEUTICS INC (FOLD)

US03152W1099 - Common Stock

11.22  +0.2 (+1.81%)

After market: 11.22 0 (0%)

News Image
17 days ago - InvestorPlace

7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps

These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.

News Image
23 days ago - Seeking Alpha

Amicus Therapeutics files to sell 2.5M shares for holders (NASDAQ:FOLD)

Selling stockholders of Amicus Therapeutics (FOLD) to offer 2.5 million shares for sale, with the company not receiving any proceeds.

News Image
24 days ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time ...

News Image
a month ago - Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023

PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...

News Image
a month ago - Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...

News Image
2 months ago - Market News Video

Notable Friday Option Activity: GME, FOLD, TGT

News Image
2 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters...

News Image
2 months ago - Seeking Alpha

Amicus in pact with Blackstone for $430M financing (NASDAQ:FOLD)

Amicus Therapeutics secures $430M in financing through a loan arrangement and equity offering with Blackstone. Read more here.

News Image
2 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON,...

News Image
2 months ago - WuXi Biologics

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...

News Image
2 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...

News Image
2 months ago - Investor's Business Daily

Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark

Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.

News Image
2 months ago - Seeking Alpha

Amicus closes up 5% as it expects approval of Pompe disease therapy (NASDAQ:FOLD)

Amicus Therapeutics expects imminent approval of its Pompe disease treatment, AT-GAA, as indicated in an updated corporate presentation.

News Image
3 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...

News Image
3 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across...

News Image
3 months ago - WuXi Biologics

WuXi Biologics Reports Solid 2023 Interim Results

Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...

News Image
3 months ago - Seeking Alpha

Amicus Therapeutics appoints CFO (NASDAQ:FOLD)

Biotechnology company Amicus Therapeutics (FOLD) said on Monday that Simon Harford has been appointed CFO, effective immediately.

News Image
3 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global...

News Image
4 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...

News Image
4 months ago - Seeking Alpha

Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook (NASDAQ:FOLD)

Amicus Therapeutics press release (FOLD): Q2 GAAP EPS of -$0.15 misses by $0.04.Revenue of $94.5M (+17.1% Y/Y) beats by $4.63M.Cash, cash equivalents, and marketable securities...

News Image
4 months ago - Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates

1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda®...